SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bhag Karamchandani who wrote (5254)9/3/1998 5:24:00 PM
From: scaram(o)uche  Read Replies (1) of 6136
 
>> I would very much appreciate your personal but specific reasons for concluding that
AG3340 was worth testing- beyond repeating the very limited and modest results
announced by AGPH. Thanks. <<

Bhag.... many here know that my interest in angiogenesis has derived from the very earliest of observations. I've followed the ENMD observations with interest, but also with the jaundiced eye of someone who worked for large pharma when Folkman first surfaced.

I can't cite reasons beyond what is public, as I have no knowledge of anything beyond that. I consider the inhibitor to be relatively potent. Further, it has passed phase I (safety) testing has good oral bioavailability. I therefore look at a variety of MMPI data beyond that which specifically relates to 3340.

Ask yourself this question, and then perhaps you'll be a bit more pensive.... how often does a Glaxo or a Merck or a Pfizer or a Bayer serve you with answers up-front? A real-world perspective will help you with this stock or with any other biotech that has transitioned to profit.

>> Ambivalent at the very least. <<

I've made it clear that this is also my stance. However, (1) I do not consider 3340 as a company cornerstone, and (2) I anxiously await clinical data so that we can more clearly evaluate the potential of MMPIs.

Rick
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News